Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Cash & Equivalents (2018 - 2025)

Historic Cash & Equivalents for Arcturus Therapeutics Holdings (ARCT) over the last 8 years, with Q3 2025 value amounting to $180.4 million.

  • Arcturus Therapeutics Holdings' Cash & Equivalents fell 2395.58% to $180.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $180.4 million, marking a year-over-year decrease of 2395.58%. This contributed to the annual value of $237.0 million for FY2024, which is 3206.23% down from last year.
  • Per Arcturus Therapeutics Holdings' latest filing, its Cash & Equivalents stood at $180.4 million for Q3 2025, which was down 2395.58% from $196.5 million recorded in Q2 2025.
  • Arcturus Therapeutics Holdings' Cash & Equivalents' 5-year high stood at $466.8 million during Q1 2021, with a 5-year trough of $180.4 million in Q3 2025.
  • Over the past 5 years, Arcturus Therapeutics Holdings' median Cash & Equivalents value was $311.9 million (recorded in 2023), while the average stood at $307.7 million.
  • As far as peak fluctuations go, Arcturus Therapeutics Holdings' Cash & Equivalents skyrocketed by 68498.6% in 2021, and later plummeted by 4257.37% in 2022.
  • Over the past 5 years, Arcturus Therapeutics Holdings' Cash & Equivalents (Quarter) stood at $370.5 million in 2021, then grew by 5.77% to $391.9 million in 2022, then decreased by 10.97% to $348.9 million in 2023, then crashed by 32.06% to $237.0 million in 2024, then fell by 23.91% to $180.4 million in 2025.
  • Its Cash & Equivalents stands at $180.4 million for Q3 2025, versus $196.5 million for Q2 2025 and $216.9 million for Q1 2025.